Why it is too soon to celebrate the Alzheimer’s ‘wonder drug’
The US approval of aducanumab — the first disease-modifying drug for Alzheimer’s disease — based on a trial with a surrogate endpoint, has caused quite a stir. Here we look at the controversy and what the approval might mean for Alzheimer’s research.…
